Microscopy innovator Chromodynamics raises €2M in funding
Eindhoven, 25 November 2025 – Deep tech company Chromodynamics announces that it has raised €2 million in Seed funding from investment fund KIKK Capital. This funding will enable Chromodynamics to complete the development of its revolutionary microscopy product and launch commercially into the biomedical research market.
Chromodynamics was founded in 2019 with a mission to deliver instruments that eliminate guesswork from drug development and prescription. Based at the High Tech Campus in Eindhoven, the company is on a path towards a global launch of its highly innovative, fully automated microscope platform, designed to autonomously identify cells in tissue samples. Addressing a strong unmet need in a large emerging market, this platform has the potential to transform biomedical research.
During drug development, hundreds of compounds need to be screened for efficacy and safety. Additionally, predicting how an individual patient will respond to a drug remains challenging due to incomplete insights into the body’s immune response. To accurately characterize an immune response, the interactions between numerous tissue components must be mapped. Conventional microscopy images and statistical datasets without spatial information (e.g., from flow cytometry) fail to deliver this essential information. Existing methods for identifying cells in tissue samples are complex, costly, and take months to complete. Chromodynamics’ end-to-end solution reduces this process to under a week.
“It is really exciting to secure the funding needed to realize our vision.”, says Wouter Vijvers, founder and CEO of Chromodynamics. “Over the past years, we have done so much market validation and technology development to prove that we have a winner in our hands. Now, we can enter the next phase. Our solution improves upon the state-of-the-art by an order of magnitude on all important performance metrics (throughput, ease-of-use, level of detail), while dramatically reducing costs for the customer. ”In KIKK Capital, the founders of Chromodynamics have found a single investor for the full amount with whom there is a great amount of mutual trust.
“From the first meeting with Chromodynamics, we were impressed by the founders and their innovative solution addressing a significant challenge in the biotech industry. As a Deep Tech investor and experienced investor in biotech platform technology, we are well-positioned to support Chromodynamics with our expertise in building successful companies and leveraging our network in the biotech industry.” says Johan Sebregts, Managing Partner at KIKK Capital.
Chromodynamics is prioritizing the completion of product development for a launch in the beachhead translational research market, with a focus on accelerating drug development, particularly immunotherapies for cancer. In the long-term, the platform is expected to evolve into a diagnostic tool for personalized medicine.
“I want to live in a world where treatments are kinder to the patient, but harsher on the disease, and known to work for each unique individual before being administered.”, adds Wouter Vijvers. “With the support of KIKK Capital, we have taken a big step towards the launch of a product that brings us closer to that future. And that is what drives our talented team to great heights.”
About Chromodynamics
Chromodynamics is a deep-tech company based in Eindhoven (NL), specializing in the development, building, and commercialization of groundbreaking microscopy products. Building on years of experience developing hyperspectral imaging systems and supported by universal praise from prospective customers for its groundbreaking potential, the company is building the next generation of research equipment for tissue analysis.
About KIKK Capital
KIKK Capital is a Deep Tech investor that partners with start-up companies to build strong, successful, and sustainable businesses. KIKK Capital supports ambitious, determined, and motivated management teams by providing not only the funding required for business growth but also by actively supporting and assisting in maximizing and leveraging growth opportunities.